• Candidemia and other serious candidal infections including intra-abdominal abscess, peritonitis.
• Esophageal candidiasis.

Contraindicated in:

• Hypersensitivity
• Known or suspected hereditary fructose intolerance.

Use Cautiously in:

• Underlying liver disease (may worsen)
• OB: Safety not established in pregnancy; other antifungal agents preferred in pregnancy for infections caused by Candida
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established in children <1 mo (candidemia and intra-abdominal abscess and peritonitis caused by Candida or <18 yr (esophageal candidiasis); may lead to polysorbate toxicity in low-birth weight infants.

CV: hypotension.

Derm: flushing, rash, urticaria.

F and E: hypokalemia.

GI: ↑ liver enzymes, diarrhea.

Resp: bronchospasm, dyspnea.

Misc: ANAPHYLAXIS, infusion reactions.

Drug-Drug:

• None reported.

• Lyophilized powder for injection (contains fructose and polysorbate 80): 50 mg/vial; 100 mg/vial;

Candidemia and Intra-abdominal Abscess or Peritonitis Caused by Candida

• IV (Adults): 200 mg loading dose on Day 1, then 100 mg once daily. Continue therapy for ≥14 days after last positive culture.
• IV (Children ≥1 mo): 3 mg/kg (max = 200 mg) loading dose on Day 1, then 1.5 mg/kg (max = 100 mg) once daily. Continue therapy for ≥14 days after last positive culture.

Esophageal Candidiasis

• IV (Adults): 100 mg loading dose on Day 1, then 50 mg once daily. Continue therapy for a minimum of 14 days and for ≥7 days following resolution of symptoms.

Eraxis

• Inhibits the synthesis of fungal cell wall.

• Death of susceptible fungi.

Spectrum:

• Active against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.

Therapeutic Classification: antifungals

Pharmacologic Classification: echinocandins

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Undergoes chemical degradation without hepatic metabolism; <1% excreted in urine.

Half-life: 40–50 hr.

(plasma concentrations)

• Explain purpose of medication to patient.
• Instruct patient to notify health care professional if signs and symptoms of anaphylaxis occur or if diarrhea becomes pronounced.
• Inform patient that anidulafungin contains fructose. May be life-threatening when administered to patients with hereditary fructose intolerance.
• Rep: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

a-NI-du-la-fun-gin

NDC Code^*

• 0049- Roerig
  • 0049-0114- ERAXIS
    • 0049-0114-28- 15 mL in 1 VIAL, SINGLE-USE (0049-0114-28)

• 0049- Roerig
  • 0049-0116- ERAXIS
    • 0049-0116-28- 30 mL in 1 VIAL, SINGLE-USE (0049-0116-28)